PureTech represent a fairly apt focus for discussion, following a flurry of visits to our local GP’s in-house vampire, a lovely lady called Fiona who regards it as her life work to extract blood from the innocent. To be honest, Fiona is a superb practice nurse (who sometimes reads my daily articles!) and can wield a needle with greater delicacy than the nurses across at the Haematology Unit. From the glint in their eyes, patients are left with the feeling they’d rather be holding a chainsaw. But Fiona is capable of filling 5 test tubes of blood, while the patient still has eyes tightly shut, expecting an imminent stab.
The problem, as happens for folk of a certain age and weight, is Type 2 Diabetes. First diagnosed a few years ago, my bloodwork had retreated to sane levels and I’d been able to stop the dreadful Diabetes medication. If offered Metformin by a GP, run, screaming. It can have terrible effects on patients toilet regimes and is probably sponsored by an underwear manufacturer. Of course, some folk have no side effects! But with the end of 30 months of chemotherapy, Fiona The Nurse was itching to stab me, demanding another look at my Type2 Diabetes bloodwork as, in her biased opinion, I’d put on weight. Quite how she spotted a 7 kilo gain defeats but apparently my body had returned to its “a wee fat bloke” default setting, boasting 101 kilos on her scales.
After talking things over with my wife, Nurse Fiona was informed the risks of Type 2 Diabetes were preferable to taking Metformin, probably the first time a prescribed drug was being refused. She arranged a meeting with the practice Pharmacist, someone I didn’t know existed. The guy listened to my Metformin anecdotes, discretely going into the loo with a full change of clothes and a black bin-bag, running into the bushes at a nature reserve, desperate to avoid eye contact with a bunch of children on mountain bikes navigating the usually deserted track, and of course, that time the “dog car” was changed for something with leather seats. This particular drug became a “quality of life” issue, along with the source of my funny stories about a fictional dog walking friend.
The Pharmacist was sympathetic, saying he’d heard about this sort of thing and pointing out I should have complained to the doctor. Maybe it’s a man thing but admitting you couldn’t risk going out in public wasn’t a welcome conversation, no matter what else was happening. After all, one has a certain self image to maintain. along with a mental voice from “Steve Wrights Old Woman” saying “mustn’t cause a fuss”…
And thus, a new drug called Ozempic was prescribed. It’s apparently also a popular weight loss drug, self administered weekly. It ticked all the boxes until Monday 7th September, when the prescription had been collected and there was the discovery I was expected to inject the stuff myself, into myself. While the needle is tiny, the process generated a bit of a scream, my wife inspecting the syringe thing and announced I’d missed, absolutely nothing had entered my body. She got that “I wish this was a chainsaw” glint in her eyes, before stabbing me. In what was a painless process. She has agreed to stab me weekly, though promises not to enjoy it.
And this brings us to PureTech Health, a company claiming to have an orally administered weight loss solution which will – from a personal perspective – successfully compete with Ozempic, though it appears the magic from PureTech isn’t intended for diabetes, just for fat people! In our book, any initiative which does not involve injections deserves extremely positive attention.
PureTech boast a share price which has been waffling around since breaking the Closing Price Downtrend Since 2021, the share price carefully respecting this historical downtrend and giving building hope for the future. Perhaps their Half Year price announcement on 22nd September is supposed to do to the share price something similar to my imaginary Ozempic needle, causing a sharp surge upward?
If we’re right – and we expect to be – above just 129 should bring a sharp surge to an initial 133p with our secondary, if bettered, at a comfortable 140.5p. This secondary target level is liable to prove important, launching the share price into a zone where a long term third level ambition of 162p makes some sense. Visually, this is our expectation.
Should things decide to go wrong, below 113 should apparently trigger reversals to an initial 109p with our secondary, if broken, at 102p. And perhaps a solid bounce. Hopefully our Type 2 Diabetes regime doesn’t discover such an issue as a break below 93 kilos will be quite welcome. Hopefully this does something to the diabetes blood results but stopping being a “wee far bloke” will be a real reward.
FUTURES
FUTURES
| Time Issued | Market | Price At Issue | Short Entry | Fast Exit | Slow Exit | Stop | Long Entry | Fast Exit | Slow Exit | Stop | Prior |
| 11:04:19PM | BRENT | 9634.8 | ‘cess | ||||||||
| 11:07:29PM | GOLD | 4410.97 | 4366 | 4320 | 4258 | 4426 | 4494 | 4525 | 4577 | 4430 | |
| 11:11:00PM | FTSE | 10813.3 | ‘cess | ||||||||
| 11:13:40PM | STOX50 | 6394.2 | |||||||||
| 10:51:32PM | GERMANY | 25988 | |||||||||
| 10:54:00PM | US500 | 7705.4 | |||||||||
| 10:56:27PM | DOW | 53103.9 | 53004 | 52786 | 52462 | 53177 | 53238 | 53321 | 53428 | 53045 | |
| 10:58:49PM | NASDAQ | 29550.5 | Success | ||||||||
| 11:01:52PM | JAPAN | 65805 |
SUCCESS above means both FAST & SLOW targets were met. ‘CESS means just the FAST target met and probably the next time it is exceeded, movement to the SLOW target shall commence.
Our commentary is in two sections. Immediately below are today’s updated comments. If our commentary remains valid, the share can be found in the bottom section which has a RED heading. Hopefully, this will mean you no longer need to flip back through previous reports. HYPERLINKS DISABLED IN THIS VERSION
Please remember, all prices are mid-price (halfway between the Buy and Sell). When we refer to a price CLOSING above a specific level, we are viewing the point where we can regard a trend as changing. Otherwise, we are simply speculating on near term trading targets. Our website is www.trendsandtargets.com.
UPDATE. We often give an initial and a secondary price. If the initial is exceeded, we still expect it to fall back but the next time the initial is bettered, the price should continue to the secondary. The converse it true with price drops.
We can be contacted at info@trendsandtargets.com. Spam filters set to maximum so only legit emails get through…
Section One – Outlook Updated Today. Click here for Section Two – Outlook Remains Valid shares
Click Epic to jump to share: LSE:ASC Asos** **LSE:SAGA SAGA Plc** **LSE:SDY Speedyhire** **LSE:STAN Standard Chartered** **LSE:TERN Tern Plc** **
********
Updated charts published on : Asos, SAGA Plc, Speedyhire, Standard Chartered, Tern Plc,
LSE:ASC Asos. Close Mid-Price: 435 Percentage Change: + 0.00% Day High: 435 Day Low: 418.5
Target met. Further movement against Asos ABOVE 435 should improve accele ……..
</p
View Previous Asos & Big Picture ***
LSE:SAGA SAGA Plc. Close Mid-Price: 628 Percentage Change: + 0.00% Day High: 644 Day Low: 628
Managing to get the share price BELOW 628 is the next problem level for S ……..
</p
View Previous SAGA Plc & Big Picture ***
LSE:SDY Speedyhire. Close Mid-Price: 16.6 Percentage Change: + 0.00% Day High: 17.3 Day Low: 16.5
If the share price of Speedyhire manages to move BELOW 16.5p, initial DOW ……..
</p
View Previous Speedyhire & Big Picture ***
LSE:STAN Standard Chartered. Close Mid-Price: 2269 Percentage Change: + 0.00% Day High: 2269 Day Low: 2244
In the event of Standard Chartered enjoying further trades beyond 2269, t ……..
</p
View Previous Standard Chartered & Big Picture ***
LSE:TERN Tern Plc. Close Mid-Price: 1 Percentage Change: + 0.00% Day High: 1.1 Day Low: 1
Continued weakness against TERN taking the price below 1p calculates as l ……..
</p
View Previous Tern Plc & Big Picture ***
*** End of “Updated Today” comments on shares. Listed below are those where commentary remains valid.
Click Epic to jump to share:LSE:AAL Anglo American** **LSE:AML Aston Martin** **LSE:AV. Aviva** **LSE:AVCT Avacta** **LSE:AZN Astrazeneca** **LSE:BARC Barclays** **LSE:BBY BALFOUR BEATTY** **LSE:BLOE Block Energy PLC** **LSE:BME B & M** **LSE:BP. BP PLC** **LSE:BT.A British Telecom** **LSE:CAR Carclo** **LSE:CNA Centrica** **LSE:CPI Capita** **LSE:DGE Diageo** **LSE:ECO ECO (Atlantic) O & G** **LSE:EMG MAN** **LSE:EXPN Experian** **LSE:EZJ EasyJet** **LSE:FGP Firstgroup** **LSE:FOXT Foxtons** **LSE:FRES Fresnillo** **LSE:GENL Genel** **LSE:GKP Gulf Keystone** **LSE:GLEN Glencore Xstra** **LSE:GRG Greggs** **LSE:HIK Hikma** **LSE:HSBA HSBC** **LSE:IAG British Airways** **LSE:IGG IG Group** **LSE:IQE IQE** **LSE:ITM ITM Power** **LSE:ITRK Intertek** **LSE:ITV ITV** **LSE:LLOY Lloyds Grp.** **LSE:MKS Marks and Spencer** **LSE:MRO Melrose** **LSE:NG. National Glib** **LSE:NWG Natwest** **LSE:OCDO Ocado Plc** **LSE:ONT Oxford Nanopore Tech** **LSE:OXIG Oxford Instruments** **LSE:PHP Primary Health** **LSE:PMG Parkmead** **LSE:QED Quadrise** **LSE:RKH Rockhopper** **LSE:RR. Rolls Royce** **LSE:SBRY Sainsbury** **LSE:SCLP Scancell** **LSE:SFOR S4 Capital** **LSE:SMT Scottish Mortgage Investment Trust** **LSE:SPX Spirax** **LSE:SRP Serco** **LSE:STAR Star Energy** **LSE:TLW Tullow** **LSE:TRN The Trainline** **LSE:TSCO Tesco** **LSE:TW. Taylor Wimpey** **LSE:VOD Vodafone** **LSE:ZOO Zoo Digital** **
********
Many thanks for taking the time to read this and good luck for today. Please feel free to mention us after something goes right!
Risk Warning & Notice to Investors
Buying, selling and investing in shares is not without risk. Market and company movement will affect your performance and you may get back less than you invest. Neither Trends and Targets Ltd, Shareprice, or Interactive Investor will be responsible for any losses that may be incurred as a result of following a trading idea.